The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

@article{Choueiri2011TheIO,
  title={The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.},
  author={Toni K Choueiri and Wanling L Xie and Christian K. Kollmannsberger and Scott North and Jennifer J. Knox and James Geoffrey Lampard and D F Mcdermott and Brian I. Rini and Daniel Yick Chin Heng},
  journal={The Journal of urology},
  year={2011},
  volume={185 1},
  pages={60-6}
}
PURPOSE Vascular endothelial growth factor targeted therapy is a standard of care in patients with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of novel agents remains poorly defined. MATERIALS AND METHODS We retrospectively reviewed baseline characteristics and outcomes of 314 patients with anti-vascular endothelial… CONTINUE READING